RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy

Source: Targeted Oncology, October 2024

During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.

KEY TAKEAWAYS FROM AHMAD TARHINI, MD, PHD
? The indirect matched cohort comparison of ipilimumab (Yervoy) plus nivolumab
(Opdivo) and nivolumab/relatlimab (Opdualag) matched patients in the 2 trials
based on baseline characteristics and follow-up time.
? Progression-free survival (PFS), overall survival (OS), and objective response rate
(ORR) showed no statistically significant differences.
? Grade 3 and 4 toxicity rates were lower with nivolumab/relatlimab.

Targeted Oncology: How can outcomes with ipilimumab plus nivolumab be compared
with those of nivolumab/relatlimab in patients with metastatic melanoma?

<ahref="https://www.targetedonc.com/view/relativity-047-vs-check mate-067-matched-cohorts-in-melanoma-show-similar-efficacy " target="_blank">READ THE ORIGINAL FULL ARTICLE